I think the stock price shows that the basher caba
Post# of 72440
Nothing has changed in terms of the amazing progress the company is making toward Phase 3 trials. Knowing that they are increasing the number of trial sites for Prurisol should be very encouraging to everyone -- they're trying to make it go as fast as possible.
Now as a comparison, let's look at another old Patrick Cox pick, NNVC. NNVC has been in existence a decade longer that CTIX, yet they don't have a single clinical trial going. They've been accused of constantly changing the target of their supposed virus-killer -- for instance, they were saying that they were going to do a clinical trial of their flu-cide, then said they were shifting their focus to Ebola because of the emergency, then golly gosh there were no longer enough Ebola cases for a clinical trial. Now they're saying they're shifting their focus to a topical cream, supposedly to work against shingles. WTF? Shingles is triggered by viruses lurking in the nerves -- how could a topical cream work, even if their nanoparticle approach actually works (of which we have had no proof in humans).
CTIX by contrast has always made steady progress through numerous clinical trials. Yes, the Kevetrin trial took a long time, because they were cautious and started at very low doses, and then it turned out to be so safe they weren't able to find a dose that made people significantly sick. But that's a good thing.
What gripes me is that the shorts didn't go after NNVC, which was a LEGITIMATE target for short selling because of their actions since inception -- but instead attacked CTIX, which is genuinely trying to save lives.